Value Investor
Start free

Aprea Therapeutics

APRE on Nasdaq. Market value $9m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

We have not checked this company yet

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 28 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%.

  • Soleus Private Equity Fund III, L.P.
    Passive investor
    at least 10.0%
    (filed with 8 related holders)
    Since 1 April 2026
  • Vestal Point Capital, LP
    Passive investor
    at least 9.9%
    (filed with 1 related holder)
    Since 31 March 2026
  • Orin Hirschman
    Passive investor
    at least 9.9%0.0 pts
    (filed with 1 related holder)
    Since 31 March 2026
  • at least 9.9%
    (filed with 3 related holders)
    Since 30 March 2026
  • at least 4.5%
    (filed with 2 related holders)
    Since 31 December 2025
  • at least 4.3%−0.8 pts
    (filed with 3 related holders)
    Since 31 March 2025
  • LYTTON LAURENCE W
    Passive investor
    Sold down below 5%
    Since 30 June 2026
  • Sold down below 5%
    Since 30 September 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 3 insiders bought $61,039 of shares on the open market.

  • Gilad Oren
    President/CEO, Director
    Bought
    Date
    30 January 2026
    Shares
    28,100
    Price
    $0.89
    Value
    $25,009
  • Hamill John P.
    SrVP/CFO/Prin Fin & Acct Ofcr
    Bought
    Date
    30 January 2026
    Shares
    5,700
    Price
    $0.89
    Value
    $5,073
  • Duey Marc
    Director
    Bought
    Date
    10 December 2025
    Shares
    21,459
    Price
    $1.17
    Value
    $25,107
  • Hamill John P.
    SrVP/CFO/Prin Fin & Acct Ofcr
    Bought
    Date
    10 December 2025
    Shares
    5,000
    Price
    $1.17
    Value
    $5,850

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 16 Mar 2026, plus the 10-Q filed 12 Aug 2026 and 7 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.